Stockscreener 앱 받기
3.50
2.51%
-0.09
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Will Arbutus Biopharma Corporation bounce back from current support2025 Major Catalysts & Growth Focused Entry Reports - Newser
Applying chart zones and confluence areas to Arbutus Biopharma CorporationCEO Change & Long-Term Capital Growth Strategies - Newser
Multi asset correlation models including Arbutus Biopharma Corporation2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Published on: 2025-08-20 02:54:05 - Newser
Chart overlay techniques for tracking Arbutus Biopharma CorporationMarket Performance Report & Reliable Breakout Forecasts - Newser
Understanding Arbutus Biopharma Corporation’s price movementMarket Activity Summary & Low Risk High Win Rate Stock Picks - Newser
Sentiment analysis tools applied to Arbutus Biopharma CorporationMarket Trend Report & Stock Portfolio Risk Control - Newser
Technical analysis overview for Arbutus Biopharma Corporation stockWatch List & Stepwise Trade Signal Guides - Newser
Measuring Arbutus Biopharma Corporation’s beta against major indicesTrade Risk Report & Expert Approved Momentum Trade Ideas - Newser
Custom watchlist performance reports with Arbutus Biopharma CorporationPortfolio Value Summary & Low Drawdown Investment Ideas - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryJuly 2025 Update & High Accuracy Trade Alerts - Newser
Published on: 2025-08-19 03:41:21 - Newser
Published on: 2025-08-19 01:06:42 - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeQuarterly Performance Summary & Low Risk High Win Rate Picks - Newser
Real time scanner hits for Arbutus Biopharma Corporation explainedMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Volatility clustering patterns for Arbutus Biopharma CorporationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Can volume confirm reversal in Arbutus Biopharma CorporationMarket Performance Summary & Weekly Breakout Stock Alerts - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataJuly 2025 Earnings & High Win Rate Trade Alerts - Newser
Real time social sentiment graph for Arbutus Biopharma CorporationQuarterly Portfolio Report & Daily Volume Surge Signals - Newser
Exit strategy if you’re trapped in Arbutus Biopharma CorporationPortfolio Update Report & Stepwise Trade Signal Guides - Newser
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Chardan Capital Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Reports Q2 2025 Revenue of $10.7M and Appoints New Board Members - SSBCrack
1.38%
0.27%
자본화:
|
볼륨(24시간):